Severe Comeal Changes following Intravitreal Injection of Bevacizumab

Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2010-08, Vol.18 (4), p.268-274
Main Authors: Bayar, SA, Altinors, D D, Kucukerdonmez, C, Akova, YA
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 274
container_issue 4
container_start_page 268
container_title Ocular immunology and inflammation
container_volume 18
creator Bayar, SA
Altinors, D D
Kucukerdonmez, C
Akova, YA
description Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab. Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period. Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.
doi_str_mv 10.3109/09273948.2010.490630
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_904484852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>904484852</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_9044848523</originalsourceid><addsrcrecordid>eNqNyr0OgjAYheEOmog_d-DQzQn8oFXpKsHIrDup5ANLSqsUMPHqlcQLcDrJc15C1iEELASxBREdmOBxEMGXuIA9gwnxRvZHn5G5czUAcCFCj6QXHLBFmtgGpabJXZoKHS2t1valTEUz07VyUF073pmpseiUNdSW9IiDLNS7b-RtSaal1A5Xv12QzSm9Jmf_0dpnj67LG-UK1FoatL3LBXAe83gXsf_LD-dXQ_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>904484852</pqid></control><display><type>article</type><title>Severe Comeal Changes following Intravitreal Injection of Bevacizumab</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Bayar, SA ; Altinors, D D ; Kucukerdonmez, C ; Akova, YA</creator><creatorcontrib>Bayar, SA ; Altinors, D D ; Kucukerdonmez, C ; Akova, YA</creatorcontrib><description>Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab. Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period. Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.</description><identifier>ISSN: 0927-3948</identifier><identifier>DOI: 10.3109/09273948.2010.490630</identifier><language>eng</language><ispartof>Ocular immunology and inflammation, 2010-08, Vol.18 (4), p.268-274</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Bayar, SA</creatorcontrib><creatorcontrib>Altinors, D D</creatorcontrib><creatorcontrib>Kucukerdonmez, C</creatorcontrib><creatorcontrib>Akova, YA</creatorcontrib><title>Severe Comeal Changes following Intravitreal Injection of Bevacizumab</title><title>Ocular immunology and inflammation</title><description>Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab. Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period. Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.</description><issn>0927-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNyr0OgjAYheEOmog_d-DQzQn8oFXpKsHIrDup5ANLSqsUMPHqlcQLcDrJc15C1iEELASxBREdmOBxEMGXuIA9gwnxRvZHn5G5czUAcCFCj6QXHLBFmtgGpabJXZoKHS2t1valTEUz07VyUF073pmpseiUNdSW9IiDLNS7b-RtSaal1A5Xv12QzSm9Jmf_0dpnj67LG-UK1FoatL3LBXAe83gXsf_LD-dXQ_A</recordid><startdate>20100801</startdate><enddate>20100801</enddate><creator>Bayar, SA</creator><creator>Altinors, D D</creator><creator>Kucukerdonmez, C</creator><creator>Akova, YA</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20100801</creationdate><title>Severe Comeal Changes following Intravitreal Injection of Bevacizumab</title><author>Bayar, SA ; Altinors, D D ; Kucukerdonmez, C ; Akova, YA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_9044848523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bayar, SA</creatorcontrib><creatorcontrib>Altinors, D D</creatorcontrib><creatorcontrib>Kucukerdonmez, C</creatorcontrib><creatorcontrib>Akova, YA</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Ocular immunology and inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bayar, SA</au><au>Altinors, D D</au><au>Kucukerdonmez, C</au><au>Akova, YA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe Comeal Changes following Intravitreal Injection of Bevacizumab</atitle><jtitle>Ocular immunology and inflammation</jtitle><date>2010-08-01</date><risdate>2010</risdate><volume>18</volume><issue>4</issue><spage>268</spage><epage>274</epage><pages>268-274</pages><issn>0927-3948</issn><abstract>Purpose: To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration. Design: Retrospective noncomparative case series. Methods: The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab. Results: Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period. Conclusions: Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.</abstract><doi>10.3109/09273948.2010.490630</doi></addata></record>
fulltext fulltext
identifier ISSN: 0927-3948
ispartof Ocular immunology and inflammation, 2010-08, Vol.18 (4), p.268-274
issn 0927-3948
language eng
recordid cdi_proquest_miscellaneous_904484852
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
title Severe Comeal Changes following Intravitreal Injection of Bevacizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A28%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20Comeal%20Changes%20following%20Intravitreal%20Injection%20of%20Bevacizumab&rft.jtitle=Ocular%20immunology%20and%20inflammation&rft.au=Bayar,%20SA&rft.date=2010-08-01&rft.volume=18&rft.issue=4&rft.spage=268&rft.epage=274&rft.pages=268-274&rft.issn=0927-3948&rft_id=info:doi/10.3109/09273948.2010.490630&rft_dat=%3Cproquest%3E904484852%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_9044848523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=904484852&rft_id=info:pmid/&rfr_iscdi=true